国际多发性硬化症微生物组研究（iMSMS）研究了576名多发性硬化症患者（36%未经治疗），和遗传上没有关系的家庭健康对照组（总共1152名受试者）的肠道微生物组。研究人员观察到嗜黏蛋白阿克曼菌（Akkermansia muciniphila）、Ruthenibacterium lactatiformans、Hungatella hathewayi和Eisenbergiella tayi的比例明显增加，Faecalibacterium prausnitzii和Blautia物种减少。植酸盐降解途径在未处理的MS中比例过高，而产生丙酮酸的碳水化合物代谢途径则明显减少。
微生物组的组成、功能和衍生的代谢物在对疾病调节治疗的反应上也有所不同。干扰素-β的治疗活性可能部分与短链脂肪酸转运体的上调有关。在未经治疗的多发性硬化症和健康对照中观察到不同的微生物网络。这些结果强烈支持特定的肠道微生物组与多发性硬化症风险、病程和进展的关系，以及对治疗反应的功能变化。
据悉，肠道微生物群的变化与几种疾病有关。
附：英文原文
Title: Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course
Author: Xiaoyuan Zhou, Ryan Baumann, Xiaohui Gao, Myra Mendoza, Sneha Singh, Ilana Katz Sand, Zongqi Xia, Laura M. Cox, Tanuja Chitnis, Hongsup Yoon, Laura Moles, Stacy J. Caillier, Adam Santaniello, Gail Ackermann, Adil Harroud, Robin Lincoln, Refujia Gomez, Antonio González Pea, Elise Digga, Daniel Joseph Hakim, Yoshiki Vazquez-Baeza, Karthik Soman, Shannon Warto, Greg Humphrey, Mauricio Farez, Lisa Ann Gerdes, Jorge R. Oksenberg, Scott S. Zamvil, Siddharthan Chandran, Peter Connick, David Otaegui, Tamara Castillo-Trivio, Stephen L. Hauser, Jeffrey M. Gelfand, Howard L. Weiner, Reinhard Hohlfeld, Hartmut Wekerle, Jennifer Graves, Amit Bar-Or, Bruce A.C. Cree, Jorge Correale, Rob Knight, Sergio E. Baranzini
Issue&Volume: 2022/09/15
Abstract: Changes in gut microbiota have been associated with several diseases. Here, the InternationalMultiple Sclerosis Microbiome Study (iMSMS) studied the gut microbiome of 576 MS patients(36% untreated) and genetically unrelated household healthy controls (1,152 totalsubjects). We observed a significantly increased proportion of Akkermansia muciniphila, Ruthenibacterium lactatiformans, Hungatella hathewayi, and Eisenbergiella tayi and decreased Faecalibacterium prausnitzii and Blautia species. The phytate degradation pathway was over-represented in untreatedMS, while pyruvate-producing carbohydrate metabolism pathways were significantly reduced.Microbiome composition, function, and derived metabolites also differed in responseto disease-modifying treatments. The therapeutic activity of interferon-β may in partbe associated with upregulation of short-chain fatty acid transporters. Distinct microbialnetworks were observed in untreated MS and healthy controls. These results stronglysupport specific gut microbiome associations with MS risk, course and progression,and functional changes in response to treatment.
DOI: 10.1016/j.cell.2022.08.021
Source: https://www.cell.com/cell/fulltext/S0092-8674(22)01115-1